GlassScriptPhysician profile
David S Harris
NPI 1215913975
$817.75
in general payments reported to CMS, 2019-2025
15 companies · $74.06 in 2025
The $74.06 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2021: $126 · 2022: $79.35 · 2023: $62.27 · 2024: $25.52 · 2025: $74.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $161.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $169.02 | 2019 | |
| Astellas Pharma US INC | $157.94 | 2019-2021 | |
| Janssen Biotech, INC. | $134.94 | 2019-2025 | Erleada |
| Novo Nordisk INC | $69.30 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Tolmar Pharmaceuticals, INC. | $56.99 | 2019-2021 | |
| Teleflex LLC | $52.34 | 2023-2025 | Barrigel, Urolift |
| Abbvie INC. | $38.57 | 2022-2024 | |
| Dendreon Pharmaceuticals LLC | $37.83 | 2019-2022 | |
| Blue Earth Diagnostics | $34.05 | 2022 | |
| Boston Scientific Corporation | $22.03 | 2019 | |
| Myriad Genetic Laboratories, INC. | $18.91 | 2023 | Prolaris |
| Allergan, INC. | $14.07 | 2021 | |
| Medtronic, INC. | $11.76 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,134,277.92 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.